Journal Scans
Early Discontinuation and Nonadherence to Adjuvant Hormonal Therapy in a Cohort of 8,769 Early-Stage Breast Cancer Patients
Low Adherence to Hormonal Therapy in Early-Stage Breast Cancer
DL Hershman, LH Kushi, T Shao, D Buono, A Kershenbaum, W-Y Tsai, L Fehrenbacher, SL Gomez, S Miles, AI Neugut
Yes
20100528
2010 Jun 28
J Clin Oncol
Early Discontinuation and Nonadherence to Adjuvant Hormonal Therapy in a Cohort of 8,769 Early-Stage Breast Cancer Patients
J Clin Oncol. 2010 Jun 28;[Epub Ahead of Print], DL Hershman, LH Kushi, T Shao, D Buono, A Kershenbaum, W-Y Tsai, L Fehrenbacher, SL Gomez, S Miles, AI Neugut
TAKE-HOME MESSAGE
EXPERT COMMENTARY
Abstract
SUMMARY
OncologySTAT Editorial Team
Adjuvant hormonal therapy with tamoxifen or an aromatase inhibitor (AI) for 5 years significantly reduces recurrence and mortality in women with hormone-sensitive breast cancer. Yet studies show that early discontinuation rates are high, and adherence rates are low, for this potentially life-saving regimen. Previous adherence studies were small and focused primarily on elderly patients. Hershman et al, using the database from Kaiser Permanente of Northern California, studied the problem in a large,...
